EU/3/13/1135

About

On 7 June 2013, orphan designation (EU/3/13/1135) was granted by the European Commission to Dompé S.p.A., Italy, for recombinant human nerve growth factor for the treatment of retinitis pigmentosa.

The sponsorship was transferred to Dompé farmaceutici s.p.a., Italy, in March 2015.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Recombinant human nerve growth factor
Disease / condition
Treatment of retinitis pigmentosa
Date of decision
07/06/2013
Outcome
Positive
Orphan decision number
EU/3/13/1135

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dompé farmaceutici s.p.a.
Via Santa Lucia 6
20122 Milano
Italy
Tel. +39 02 58 38 35 59
Fax +39 02 36 02 69 27
E-mail: info@dompe.it

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating